About 428 Pharma

About company

A team of former senior Teva directors with combined 60+ years and more than 60 projects in diagnostics and 505(b)(2) drug development have secured exclusive worldwide rights to two of the most promising Teva assets, made available by Teva’s recent well-publicized R&D restructuring and divestment.